(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Chromosomal Microarray Reflex Testing Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global chromosomal microarray reflex testing market is experiencing strong growth as healthcare providers increase their use of advanced genomic diagnostics for prenatal, postnatal, oncology, and rare disease applications. The market is projected to grow from $1.39 billion in 2025 to $1.51 billion in 2026, representing a compound annual growth rate (CAGR) of 8.9%. Historical growth has been supported by greater awareness of genetic disorders, wider adoption of array comparative genomic hybridization, increased investment in molecular diagnostics, expansion of hospital and laboratory infrastructure, and rising demand for accurate prenatal testing.
Looking ahead, the chromosomal microarray reflex testing market is forecast to reach $2.15 billion by 2030, expanding at a CAGR of 9.1%. Key growth factors include increasing adoption of next-generation sequencing-based arrays, demand for personalized medicine, broader use of genomic testing in oncology and rare disease diagnosis, and greater integration of genomic data analysis software. Laboratories are also investing in high-throughput, automated array platforms to improve testing efficiency, accuracy, and scalability.
Major chromosomal microarray reflex testing market trends include the adoption of high-resolution arrays and growing demand for pre- and post-natal genetic testing. Single nucleotide polymorphism arrays are becoming more closely integrated with clinical workflows, while custom and multiplexed array designs are supporting increasingly specialized diagnostic requirements. These developments are expanding the clinical value of chromosomal microarray testing across hospitals, diagnostic laboratories, academic institutions, and research facilities.
The rising incidence of genetic disorders is a significant driver of market growth. Delayed parenthood and advanced maternal age can increase the risk of chromosomal abnormalities, expanding the population requiring genetic assessment. Chromosomal microarray testing can identify submicroscopic deletions, duplications, and copy number variations that may not be detected through conventional karyotyping, supporting more precise diagnoses and informed clinical decisions. According to the Cystic Fibrosis Trust, the number of people living with cystic fibrosis in the UK increased from 11,148 in 2022 to 11,318 in 2023, highlighting the continuing need for effective genetic testing and disease management.
Expansion of prenatal screening is also accelerating demand for chromosomal microarray reflex testing. Its integration into prenatal diagnostic pathways enables more comprehensive analysis of fetal chromosomal abnormalities and supports timely healthcare planning. Growing screening participation and improvements in maternal-fetal medicine are expected to strengthen adoption. In January 2026, the UK National Health Service reported that the national performance rate for fetal anomaly ultrasound screening reached 97% during the second quarter of 2024-2025.
Increasing emphasis on personalized medicine is creating additional opportunities for chromosomal microarray reflex testing. Identification of chromosomal imbalances and copy number variations can help clinicians refine diagnostic, prognostic, and therapeutic strategies based on individual genomic characteristics. This approach may also reduce reliance on sequential or invasive diagnostic procedures. The Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized therapies for rare disease patients in 2023, compared with six in 2022, demonstrating the accelerating role of genomics in targeted healthcare.
The market encompasses array comparative genomic hybridization, single nucleotide polymorphism arrays, and other technologies. Product categories include consumables, instruments, and software, with applications spanning genetic disease diagnosis, oncology, prenatal testing, postnatal testing, and related clinical areas. Continued investment in laboratory automation, bioinformatics, and high-resolution genomic analysis is expected to improve testing capacity and support wider clinical adoption.
North America was the largest region in the chromosomal microarray reflex testing market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.
Markets Covered:
1) By Technology: Array Comparative Genomic Hybridization; Single Nucleotide Polymorphism Arrays; Other Technologies
2) By Product Type: Consumables; Instruments; Software
3) By Application: Genetic Disease Diagnosis; Oncology; Pre- And Post-Natal Testing; Other Applications
4) By End-User: Hospitals and Clinics; Diagnostic Laboratories; Research and Academic Institutes; Other End-Users
Subsegments:
1) By Array Comparative Genomic Hybridization: Oligonucleotide Arrays; Bacterial Artificial Chromosome Arrays; cDNA Arrays; Custom Designed Arrays
2) By Single Nucleotide Polymorphism Arrays: High Density SNP Arrays; Low Density SNP Arrays; Genome Wide SNP Arrays; Targeted SNP Arrays
3) By Other Technologies: Multiplex Ligation Dependent Probe Amplification; Next Generation Sequencing Based Arrays; Fluorescence In Situ Hybridization; Quantitative PCR Based Arrays
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment